Posted:
#1
"June 15 is D-Day for Encysive Pharmaceuticals Inc. (Nasdaq: ENCY). It’s the day that the Houston, Tx.-based biopharmaceutical firm will find out whether the FDA has finally given the green light to its pulmonary arterial hypertension (PAH) drug, Thelin, after more than a year of review.
If the drug gets approved, beleaguered Encysive could take the lead in the race to get a new PAH drug to market in the United States. Three days later, on June 18, competitor Gilead (Nasdaq: GILD) is scheduled to find out whether its PAH drug, Ambrisentan, gets an FDA nod."-associated press
if approved. stock up 2 dollars likely. its already approved in europe why not?0
wow!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Hot Forum Topics
